Rose Pharma
Clinical-stage biopharmaceutical company developing a short-acting GLP-1 analogue (ROSE-010) for mealtime appetite control/weight-management and on-demand treatment of acute IBS pain. The company has completed multiple human clinical trials, conducted preclinical inhaled-delivery studies, holds patent protection around liquid and inhalable formulations, and pursues licensing and partnership opportunities for formulation, development and manufacturing.
Industries
Nr. of Employees
small (1-50)
Patents
Methods of treatment with stable liquid formulations of glucagon-like peptide 1 or analogues thereof
US-11980655-B2
View DetailsStable liquid formulations of glucagon-like peptide 1 or analogues thereof
US-11058748-B2
View Details
Methods of treatment with stable liquid formulations of glucagon-like peptide 1 or analogues thereof
US-11980655-B2
View DetailsStable liquid formulations of glucagon-like peptide 1 or analogues thereof
US-11058748-B2
View DetailsProducts
ROSE-010 (investigational GLP-1 analogue)
An investigational short-acting GLP-1 receptor agonist developed for rapid onset and short duration of effect; evaluated by subcutaneous dosing and explored for inhaled dry-powder delivery.
ROSE-010
A novel short-acting GLP-1 therapy designed for severe, acute IBS pain relief and long-term weight loss success.
ROSE-010 (investigational GLP-1 analogue)
An investigational short-acting GLP-1 receptor agonist developed for rapid onset and short duration of effect; evaluated by subcutaneous dosing and explored for inhaled dry-powder delivery.
ROSE-010
A novel short-acting GLP-1 therapy designed for severe, acute IBS pain relief and long-term weight loss success.
Services
Partnering to develop inhaled and other formulations, including transfer of inhalation platform use rights and provision of pharmaceutical development and manufacturing support through early clinical studies.
Execution of early-phase clinical studies and dissemination of results via scientific posters and conference presentations.
Partnering to develop inhaled and other formulations, including transfer of inhalation platform use rights and provision of pharmaceutical development and manufacturing support through early clinical studies.
Execution of early-phase clinical studies and dissemination of results via scientific posters and conference presentations.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Obesity and weight-maintenance therapeutics
- IBS acute pain therapeutics
- Pulmonary drug delivery and inhaled formulation development
Key Technologies
- Short-acting GLP-1 receptor agonist (peptide therapeutic)
- Dry-powder inhalation delivery
- Subcutaneous injection dosing
- Randomized, double-blind, placebo-controlled trial design
News & Updates
Announcement of poster presentation detailing blinded, placebo-controlled Phase 2a data on mealtime food intake, caloric reduction, satiety, GI tolerability, safety, and weight loss.
Licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 formulation using a dry-powder inhalation platform; partner to provide formulation and manufacturing support through Phase 1b.
Narrative review in Journal of Clinical Medicine discussing evidence for short-acting GLP-1 receptor modulation in acute IBS pain and reviewing previously published clinical research.
Announcement that an IRB-approved patient-preference study examining attributes of GLP-1 treatment profiles was accepted for poster presentation at ObesityWeek 2026.
Summary and link to a narrative review in the Journal of Clinical Medicine that examines prior clinical research on the investigational short-acting GLP-1 in acute IBS pain.
Announcement of poster presentation detailing blinded, placebo-controlled Phase 2a data on mealtime food intake, caloric reduction, satiety, GI tolerability, safety, and weight loss.
Licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 formulation using a dry-powder inhalation platform; partner to provide formulation and manufacturing support through Phase 1b.
Narrative review in Journal of Clinical Medicine discussing evidence for short-acting GLP-1 receptor modulation in acute IBS pain and reviewing previously published clinical research.
Announcement that an IRB-approved patient-preference study examining attributes of GLP-1 treatment profiles was accepted for poster presentation at ObesityWeek 2026.
Summary and link to a narrative review in the Journal of Clinical Medicine that examines prior clinical research on the investigational short-acting GLP-1 in acute IBS pain.